Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—an observational study from the Lupus-Cruces cohort

Abstract

The effects of aPL on damage accrual in SLE patients have been reduced over recent years. The widespread use of HCQ and a better thromboprophylaxis are likely causing this change.